Latest Content

This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.

The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.

The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.

Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.

Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.

Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.

Zachary Keaney, CPOA, discusses the lens care steps patients skip most often and why early diagnosis of lens-related keratitis is critical.

Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier time points.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.